Online inquiry

IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4123MR)

This product GTTS-WQ4123MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ICAM1 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000201.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3383
UniProt ID P05362
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ4123MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9212MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMMU-106
GTTS-WQ2503MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 212
GTTS-WQ15225MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA TACI-Fc
GTTS-WQ8651MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ14638MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ1131MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-927
GTTS-WQ892MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-181
GTTS-WQ8473MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA HTI-1088
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW